Clinical Trial

VK2735 for Weight Management Phase 3

Study acronym: VANQUISH 1
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) with one or more weight related comorbid condition without Type 2 Diabetes.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2025-07-29; most recent amendment 2025-11-20.
Status change: Recruiting → Active, Not Recruiting 2025-11-20
Trial Details
NCT Number NCT07104500
Lead Sponsor Viking Therapeutics, Inc.
Conditions Weight Loss
Enrollment 4,500 participants
Start Date 2025-06-23
Primary Completion 2027-07-01 (estimated)
Study Completion 2027-08-01 (estimated)
Updated on ClinicalTrials.gov 2025-11-24